|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||6.64 / 10.02|
MIMEDX'S PURION PROCESSED dHACM ALLOGRAFTS REPRESENT YEARS OF SCIENTIFIC RIGOR THAT CONFORM TO THE NEW USP-NF MONOGRAPH
In trading on Thursday, shares of MiMedx Group Inc crossed below their 200 day moving average of $8.03, changing hands as low as $7.87 per share. MiMedx Group Inc shares are currently trading down about 5.9% on the day.
MiMedx EpiFix®, AmnioFix®, AmnioFill™ and EpiCord™ Showcased for Wound Healing and Surgical Procedures
$64.4 Million Q3 2016 Revenue is 31% Increase Over Q3 2015
Presentation of Application Techniques and Therapeutic Approaches Using MiMedx EpiFix and AmnioFix for Wound Healing and Surgical Procedures
PRESENTERS OVERWHELMINGLY ASK FDA TO WITHDRAW OR SIGNIFICANTLY MODIFY DRAFT GUIDANCE
Study quantifies in MiMedx dHACM allografts numerous matrix components, growth factors, proteases and protease inhibitors known to play a role in wound healing
AMNIOFILL™ IS THE FIRST PRODUCT IN THE MIMEDX PLACENTAL COLLAGEN MATRIX FAMILY TO BE COMMERCIALLY INTRODUCED
FDA AGREES TO SHORTEN IMMUNOGENIC TESTING BY ONE YEAR IN THE COMPANY'S PLANTAR FASCIITIS STUDY
Trade-Ideas LLC identified MiMedx Group (MDXG) as a weak on high relative volume candidate
New Lyophilized OrthoFlo version is an advancement in product logistics and safety
$57.3 MILLION Q2 2016 REVENUE IS 26% INCREASE OVER Q2 2015
In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.34, changing hands as high as $8.38 per share. MiMedx Group Inc shares are currently trading up about 2.7% on the day.
Case series determines wounds with exposed bone or tendon treated with dHACM and STSG is viable low-cost treatment alternative to the gold standard for limb salvage
The wound care provider filed the suit for allegedly falsifying and misleading consumers with clinical data.
Company Reiterates Second Quarter Guidance
Trade-Ideas LLC identified MiMedx Group (MDXG) as a strong on high relative volume candidate